Mehdi Hamadani, MD

Professor of Internal Medicine

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Hematology
Medical Oncology

Languages

English, Urdu, Hindi, Punjabi

Cancer Center - Froedtert Hospital

(414) 805-0505

Moorland Reserve Health Center

(262) 798-7200

Education

MD - Doctor of Medicine

Biography

Mehdi Hamadani, MD, is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology & Oncology, specializing in lymphoma, and bone marrow transplantation. Dr. Hamadani serves as the Director of the Adult Blood and Marrow Transplant Program (BMT) at Froedtert Hospital. He graduated from King Edward Medical College (with honors) in Pakistan in 2001, he then completed his internal medicine residency at Oklahoma University Health Sciences Center and a Fellowship in Hematology and Oncology at The Ohio State University. He received the James V. Warren Award for Accomplishments as The Most Outstanding Research Fellow, during his fellowship.

Research Interests

Dr. Hamadani has authored over 200 peer-reviewed publications, and has been invited as a speaker for several national and international meetings. He is the recipient of Conquer Cancer Foundation of ASCO Career Development Award and ASBMT New Investigator Award. Dr. Hamadani has also received several Best Attending Physician, Outstanding Teacher, Press Ganey Top Provider and Best Doctors in America Awards. His clinical research focuses on lymphoid malignancies and hematopoietic cell transplantation. Dr. Hamadani is board certified in Hematology and Medical Oncology.

Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.

(Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB.) Am J Hematol. 2021 Nov 01;96(11):1374-1384 PMID: 34324220 PMCID: PMC8511300 07/30/2021
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy.

(Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, Hamadani M.) Blood. 2021 10 07;138(14):1278-1281 PMID: 34339501 PMCID: PMC8332674 SCOPUS ID: 2-s2.0-85114112109 08/03/2021
Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

(Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M.) Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):e775-e781 PMID: 34257042 SCOPUS ID: 2-s2.0-85110347842 07/15/2021
Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.

(Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A, Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, Hamadani M.) Blood Adv. 2021 Sep 28;5(18):3528-3539 PMID: 34496026 09/09/2021
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma.

(Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS.) Transplant Cell Ther. 2021 09;27(9):720-728 PMID: 34452722 PMCID: PMC8447221 08/29/2021
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

(Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM.) Transplant Cell Ther. 2021 Aug 27 PMID: 34461278 08/31/2021
Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.

(Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSG, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, Nishihori T, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM.) Transplant Cell Ther. 2021 Aug 24 PMID: 34450333 SCOPUS ID: 2-s2.0-85116436482 08/28/2021
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma.

(Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS.) Bone Marrow Transplant. 2021 Aug 20 PMID: 34413469 08/21/2021
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.

(Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA.) Transplant Cell Ther. 2021 08;27(8):642-649 PMID: 34304802 SCOPUS ID: 2-s2.0-85111026486 07/27/2021
The impact of post-hematopoietic stem cell transplant tyrosine kinase inhibitors in Philadelphia-positive acute lymphoblastic leukemia.

(Halahleh K, Al Rimawi D, Abu Ghosh A, Muradi I, Da'na W, Hamadani M.) Hematol Oncol Stem Cell Ther. 2021 Jul 29 PMID: 34352199 08/06/2021
Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis.

(Abboud R, Wan F, Mariotti J, Arango M, Castagna L, Romee R, Hamadani M, Chhabra S.) Bone Marrow Transplant. 2021 Jul 14 PMID: 34262142 07/16/2021
Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis.

(Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M.) Br J Haematol. 2021 Jul 12 PMID: 34254289 07/14/2021